Cargando…

Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension

BACKGROUND: TNFα levels are increased in liver cirrhosis even in the absence of infection, most likely owing to a continuous endotoxin influx into the portal blood. Soluble TNFα receptors (sTNFR type I and II) reflect release of the short-lived TNFα, because they are cleaved from the cells after bin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trebicka, Jonel, Krag, Aleksander, Gansweid, Stefan, Schiedermaier, Peter, Strunk, Holger M., Fimmers, Rolf, Strassburg, Christian P., Bendtsen, Fleming, Møller, Søren, Sauerbruch, Tilman, Spengler, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873322/ https://www.ncbi.nlm.nih.gov/pubmed/24386183 http://dx.doi.org/10.1371/journal.pone.0083341

Ejemplares similares

Future therapy of portal hypertension in liver cirrhosis – a guess
por: Sauerbruch, Tilman, et al.
Publicado: (2014)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

The Role of miRNA-34a as a Prognostic Biomarker for Cirrhotic Patients with Portal Hypertension Receiving TIPS
por: Jansen, Christian, et al.
Publicado: (2014)

Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS
por: Queck, Alexander, et al.
Publicado: (2020)

Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
por: Sauerbruch, Tilman, et al.
Publicado: (2021)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
por: Iwakiri, Yasuko, et al.
Publicado: (2021)

Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis
por: Praktiknjo, Michael, et al.
Publicado: (2018)

Etiology and Complications of Portal Vein Thrombosis
por: Trebicka, Jonel, et al.
Publicado: (2014)

Pre-primary and Primary Prophylaxis of Variceal Hemorrhage
por: Sauerbruch, Tilman, et al.
Publicado: (2013)

PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension
por: Jansen, Christian, et al.
Publicado: (2014)

Portal vein thrombosis in patients with cirrhosis
por: von Köckritz, Leona, et al.
Publicado: (2017)

Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments
por: Herath, Chandana B., et al.
Publicado: (2022)

Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis
por: Klein, Sabine, et al.
Publicado: (2015)

Role of circulating angiogenin levels in portal hypertension and TIPS
por: Queck, Alexander, et al.
Publicado: (2021)

Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension
por: Klein, Sabine, et al.
Publicado: (2016)

Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats
por: Schierwagen, Robert, et al.
Publicado: (2013)

Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension
por: Uschner, Frank E., et al.
Publicado: (2015)

Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study
por: Krag, Aleksander, et al.
Publicado: (2014)

Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021)

Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis
por: Torp, Nikolaj, et al.
Publicado: (2021)

High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal
por: Kjærgaard, Maria, et al.
Publicado: (2017)

Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites
por: Lutz, Philipp, et al.
Publicado: (2014)

Von Willebrand and Factor VIII Portosystemic Circulation Gradient in Cirrhosis: Implications for Portal Vein Thrombosis
por: Praktiknjo, Michael, et al.
Publicado: (2020)

Corrigendum to ‘Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis’ [JHEP Reports 3 (2021) 100287]
por: Torp, Nikolaj, et al.
Publicado: (2021)

Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension
por: Leeming, D J, et al.
Publicado: (2013)

Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS)
por: Chang, Johannes, et al.
Publicado: (2020)

The Use of Rifaximin in Patients With Cirrhosis
por: Caraceni, Paolo, et al.
Publicado: (2021)

Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial
por: Kronborg, Thit M., et al.
Publicado: (2023)

TIPS and splenorenal shunt for complications of portal hypertension in chronic hepatosplenic schistosomiasis–A case series and review of the literature
por: Nordmann, Tamara, et al.
Publicado: (2021)

The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis
por: Reiberger, Thomas, et al.
Publicado: (2023)

Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal Models
por: Chang, Johannes, et al.
Publicado: (2021)

Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis
por: Benz, Fabian, et al.
Publicado: (2020)

Coinheritance of hereditary spherocytosis and reversibility of cirrhosis in a young female patient with hereditary hemochromatosis
por: Höblinger, A, et al.
Publicado: (2009)

Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis
por: Queck, Alexander, et al.
Publicado: (2019)

Shunt-Induced Hepatic Encephalopathy in TIPS: Current Approaches and Clinical Challenges
por: Schindler, Philipp, et al.
Publicado: (2020)

Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats
por: Cremonese, Carla, et al.
Publicado: (2020)

Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial
por: Madsen, Bjørn Stæhr, et al.
Publicado: (2018)

Severe abnormal Heart Rate Turbulence Onset is associated with deterioration of liver cirrhosis
por: Jansen, Christian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_92062041elao9pdtf4nskersl2